{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T14:56:24Z","timestamp":1787756184405,"version":"build-2784847793"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2013,8,9]],"date-time":"2013-08-09T00:00:00Z","timestamp":1376006400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1007\/s00277-013-1862-6","type":"journal-article","created":{"date-parts":[[2013,8,8]],"date-time":"2013-08-08T09:24:11Z","timestamp":1375953851000},"page":"1379-1388","source":"Crossref","is-referenced-by-count":32,"title":["Feasibility of clofarabine cytoreduction followed by haploidentical hematopoietic stem cell transplantation in patients with relapsed or refractory advanced acute leukemia"],"prefix":"10.1007","volume":"92","author":[{"given":"Johanna","family":"Tischer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans Joachim","family":"Stemmler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Engel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Hubmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Fritsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dusan","family":"Prevalsek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Schulz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna K.","family":"Zoellner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veit","family":"B\u00fccklein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Ledderose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Hausmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,8,9]]},"reference":[{"issue":"8","key":"1862_CR1","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/sj.bmt.1704645","volume":"34","author":"M Eapen","year":"2004","unstructured":"Eapen M, Giralt SA, Horowitz MM, Klein JP, Wagner JE, Zhang MJ, Tallman MS, Marks DI, Camitta BM, Champlin RE, Ringden O, Bredeson CN, Martino R, Gale RP, Cairo MS, Litzow MR, deLima M (2004) Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant. Bone Marrow Transplant 34(8):721\u2013727. doi: 10.1038\/sj.bmt.1704645","journal-title":"Bone Marrow Transplant"},{"issue":"24","key":"1862_CR2","doi-asserted-by":"crossref","first-page":"5675","DOI":"10.1200\/JCO.2005.07.061","volume":"23","author":"C Schmid","year":"2005","unstructured":"Schmid C, Schleuning M, Ledderose G, Tischer J, Kolb HJ (2005) Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol 23(24):5675\u20135687. doi: 10.1200\/JCO.2005.07.061","journal-title":"J Clin Oncol"},{"issue":"3","key":"1862_CR3","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1182\/blood-2005-10-4165","volume":"108","author":"C Schmid","year":"2006","unstructured":"Schmid C, Schleuning M, Schwerdtfeger R, Hertenstein B, Mischak-Weissinger E, Bunjes D, Harsdorf SV, Scheid C, Holtick U, Greinix H, Keil F, Schneider B, Sandherr M, Bug G, Tischer J, Ledderose G, Hallek M, Hiddemann W, Kolb HJ (2006) Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation. Blood 108(3):1092\u20131099. doi: 10.1182\/blood-2005-10-4165","journal-title":"Blood"},{"issue":"3","key":"1862_CR4","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1159\/000319630","volume":"124","author":"M Breccia","year":"2010","unstructured":"Breccia M, Capria S, Iori AP, Foa R, Alimena G, Meloni G (2010) Clofarabine-based regimen as useful bridge therapy for allogeneic transplantation in myeloid blast crisis of Philadelphia-positive chronic myeloid leukemia resistant to imatinib and dasatinib. Acta Haematol 124(3):150\u2013152. doi: 10.1159\/000319630","journal-title":"Acta Haematol"},{"issue":"12","key":"1862_CR5","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.3109\/10428190903350413","volume":"50","author":"GU Grigoleit","year":"2009","unstructured":"Grigoleit GU, Kapp M, Tan SM, Unzicker C, Einsele H, Mielke S, Topp MS, Stuhler G (2009) Clofarabine-based salvage chemotherapy for relapsed or refractory acute leukemia before allogeneic stem cell transplantation: results from a case series. Leuk Lymphoma 50(12):2071\u20132074. doi: 10.3109\/10428190903350413","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"1862_CR6","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1177\/0091270010372519","volume":"51","author":"J Long-Boyle","year":"2011","unstructured":"Long-Boyle J, Huang J, Rydholm N, Smith A, Orchard P, Tolar J, Jacobson P (2011) Pharmacokinetics of clofarabine in patients with high-risk inherited metabolic disorders undergoing brain-sparing hematopoietic cell transplantation. J Clin Pharmacol 51(5):679\u2013686. doi: 10.1177\/0091270010372519","journal-title":"J Clin Pharmacol"},{"issue":"6","key":"1862_CR7","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1182\/blood-2007-03-081364","volume":"110","author":"JE Karp","year":"2007","unstructured":"Karp JE, Ricklis RM, Balakrishnan K, Briel J, Greer J, Gore SD, Smith BD, McDevitt MA, Carraway H, Levis MJ, Gandhi V (2007) A phase 1 clinical-laboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemias. Blood 110(6):1762\u20131769. doi: 10.1182\/blood-2007-03-081364","journal-title":"Blood"},{"issue":"26","key":"1862_CR8","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.2174\/092986706778742918","volume":"13","author":"T Robak","year":"2006","unstructured":"Robak T, Lech-Maranda E, Korycka A, Robak E (2006) Purine nucleoside analogs as immunosuppressive and antineoplastic agents: mechanism of action and clinical activity. Curr Med Chem 13(26):3165\u20133189","journal-title":"Curr Med Chem"},{"issue":"17","key":"1862_CR9","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMra052638","volume":"354","author":"EA Copelan","year":"2006","unstructured":"Copelan EA (2006) Hematopoietic stem-cell transplantation. N Engl J Med 354(17):1813\u20131826. doi: 10.1056\/NEJMra052638","journal-title":"N Engl J Med"},{"issue":"2","key":"1862_CR10","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/sj.bmt.1705011","volume":"36","author":"C Hosing","year":"2005","unstructured":"Hosing C, Saliba RM, Shahjahan M, Estey EH, Couriel D, Giralt S, Andersson B, Champlin RE, De Lima M (2005) Disease burden may identify patients more likely to benefit from second allogeneic hematopoietic stem cell transplantation to treat relapsed acute myelogenous leukemia. Bone Marrow Transplant 36(2):157\u2013162. doi: 10.1038\/sj.bmt.1705011","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"1862_CR11","doi-asserted-by":"crossref","first-page":"237","DOI":"10.5581\/1516-8484.20110060","volume":"33","author":"UD Bayraktar","year":"2011","unstructured":"Bayraktar UD, de Lima M, Ciurea SO (2011) Advances in haploidentical stem cell transplantation. Rev Bras Hematol Hemoter 33(3):237\u2013241. doi: 10.5581\/1516-8484.20110060","journal-title":"Rev Bras Hematol Hemoter"},{"issue":"11","key":"1862_CR12","doi-asserted-by":"crossref","first-page":"3948","DOI":"10.1182\/blood.V84.11.3948.bloodjournal84113948","volume":"84","author":"F Aversa","year":"1994","unstructured":"Aversa F, Tabilio A, Terenzi A, Velardi A, Falzetti F, Giannoni C, Iacucci R, Zei T, Martelli MP, Gambelunghe C et al (1994) Successful engraftment of T-cell-depleted haploidentical \"three-loci\" incompatible transplants in leukemia patients by addition of recombinant human granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells to bone marrow inoculum. Blood 84(11):3948\u20133955","journal-title":"Blood"},{"issue":"6","key":"1862_CR13","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","volume":"14","author":"L Luznik","year":"2008","unstructured":"Luznik L, O\u2019Donnell PV, Symons HJ, Chen AR, Leffell MS, Zahurak M, Gooley TA, Piantadosi S, Kaup M, Ambinder RF, Huff CA, Matsui W, Bolanos-Meade J, Borrello I, Powell JD, Harrington E, Warnock S, Flowers M, Brodsky RA, Sandmaier BM, Storb RF, Jones RJ, Fuchs EJ (2008) HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 14(6):641\u2013650. doi: 10.1016\/j.bbmt.2008.03.005","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"1862_CR14","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/bmt.2009.189","volume":"45","author":"SO Ciurea","year":"2010","unstructured":"Ciurea SO, Saliba R, Rondon G, Pesoa S, Cano P, Fernandez-Vina M, Qureshi S, Worth LL, McMannis J, Kebriaei P, Jones RB, Korbling M, Qazilbash M, Shpall EJ, Giralt S, de Lima M, Champlin RE, Gajewski J (2010) Reduced-intensity conditioning using fludarabine, melphalan and thiotepa for adult patients undergoing haploidentical SCT. Bone Marrow Transplant 45(3):429\u2013436. doi: 10.1038\/bmt.2009.189","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"1862_CR15","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1182\/blood-2003-02-0430","volume":"102","author":"Y Kanda","year":"2003","unstructured":"Kanda Y, Chiba S, Hirai H, Sakamaki H, Iseki T, Kodera Y, Karasuno T, Okamoto S, Hirabayashi N, Iwato K, Maruta A, Fujimori Y, Furukawa T, Mineishi S, Matsuo K, Hamajima N, Imamura M (2003) Allogeneic hematopoietic stem cell transplantation from family members other than HLA-identical siblings over the last decade (1991\u20132000). Blood 102(4):1541\u20131547. doi: 10.1182\/blood-2003-02-0430","journal-title":"Blood"},{"issue":"7","key":"1862_CR16","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1182\/blood-2007-02-072405","volume":"110","author":"T Kawase","year":"2007","unstructured":"Kawase T, Morishima Y, Matsuo K, Kashiwase K, Inoko H, Saji H, Kato S, Juji T, Kodera Y, Sasazuki T (2007) High-risk HLA allele mismatch combinations responsible for severe acute graft-versus-host disease and implication for its molecular mechanism. Blood 110(7):2235\u20132241. doi: 10.1182\/blood-2007-02-072405","journal-title":"Blood"},{"issue":"12","key":"1862_CR17","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","volume":"11","author":"AH Filipovich","year":"2005","unstructured":"Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, Martin P, Chien J, Przepiorka D, Couriel D, Cowen EW, Dinndorf P, Farrell A, Hartzman R, Henslee-Downey J, Jacobsohn D, McDonald G, Mittleman B, Rizzo JD, Robinson M, Schubert M, Schultz K, Shulman H, Turner M, Vogelsang G, Flowers ME (2005) National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 11(12):945\u2013956. doi: 10.1016\/j.bbmt.2005.09.004","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"1862_CR18","first-page":"825","volume":"15","author":"D Przepiorka","year":"1995","unstructured":"Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, Thomas ED (1995) 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 15(6):825\u2013828","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"1862_CR19","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","volume":"106","author":"ML Sorror","year":"2005","unstructured":"Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, Storer B (2005) Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 106(8):2912\u20132919. doi: 10.1182\/blood-2005-05-2004","journal-title":"Blood"},{"issue":"10","key":"1862_CR20","doi-asserted-by":"crossref","first-page":"3864","DOI":"10.1182\/blood.V89.10.3864","volume":"89","author":"PJ Henslee-Downey","year":"1997","unstructured":"Henslee-Downey PJ, Abhyankar SH, Parrish RS, Pati AR, Godder KT, Neglia WJ, Goon-Johnson KS, Geier SS, Lee CG, Gee AP (1997) Use of partially mismatched related donors extends access to allogeneic marrow transplant. Blood 89(10):3864\u20133872","journal-title":"Blood"},{"issue":"9","key":"1862_CR21","doi-asserted-by":"crossref","first-page":"3574","DOI":"10.1182\/blood-2008-02-140095","volume":"112","author":"F Ciceri","year":"2008","unstructured":"Ciceri F, Labopin M, Aversa F, Rowe JM, Bunjes D, Lewalle P, Nagler A, Di Bartolomeo P, Lacerda JF, Lupo Stanghellini MT, Polge E, Frassoni F, Martelli MF, Rocha V (2008) A survey of fully haploidentical hematopoietic stem cell transplantation in adults with high-risk acute leukemia: a risk factor analysis of outcomes for patients in remission at transplantation. Blood 112(9):3574\u20133581. doi: 10.1182\/blood-2008-02-140095","journal-title":"Blood"},{"issue":"4","key":"1862_CR22","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1111\/j.1365-2141.1991.tb08083.x","volume":"79","author":"AJ Barrett","year":"1991","unstructured":"Barrett AJ, Locatelli F, Treleaven JG, Gratwohl A, Szydlo R, Zwaan FE (1991) Second transplants for leukaemic relapse after bone marrow transplantation: high early mortality but favourable effect of chronic GVHD on continued remission. A report by the EBMT Leukaemia Working Party. Br J Haematol 79(4):567\u2013574","journal-title":"Br J Haematol"},{"issue":"1","key":"1862_CR23","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/bmt.2011.15","volume":"47","author":"C Schmid","year":"2012","unstructured":"Schmid C, Schleuning M, Tischer J, Holler E, Haude KH, Braess J, Haferlach C, Baurmann H, Oruzio D, Hahn J, Spiekermann K, Schlimok G, Schwerdtfeger R, Buechner T, Hiddemann W, Kolb HJ (2012) Early allo-SCT for AML with a complex aberrant karyotype\u2014results from a prospective pilot study. Bone Marrow Transplant 47(1):46\u201353. doi: 10.1038\/bmt.2011.15","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"1862_CR24","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1200\/JCO.2005.03.8554","volume":"24","author":"S Jeha","year":"2006","unstructured":"Jeha S, Gaynon PS, Razzouk BI, Franklin J, Kadota R, Shen V, Luchtman-Jones L, Rytting M, Bomgaars LR, Rheingold S, Ritchey K, Albano E, Arceci RJ, Goldman S, Griffin T, Altman A, Gordon B, Steinherz L, Weitman S, Steinherz P (2006) Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. J Clin Oncol 24(12):1917\u20131923. doi: 10.1200\/JCO.2005.03.8554","journal-title":"J Clin Oncol"},{"issue":"12","key":"1862_CR25","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1002\/ajh.23308","volume":"87","author":"B Scappini","year":"2012","unstructured":"Scappini B, Gianfaldoni G, Caracciolo F, Mannelli F, Biagiotti C, Romani C, Pogliani EM, Simonetti F, Borin L, Fanci R, Cutini I, Longo G, Susini MC, Angelucci E, Bosi A (2012) Cytarabine and clofarabine after high-dose cytarabine in relapsed or refractory AML patients. Am J Hematol 87(12):1047\u20131051. doi: 10.1002\/ajh.23308","journal-title":"Am J Hematol"},{"issue":"1","key":"1862_CR26","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1182\/blood-2005-08-3294","volume":"108","author":"S Faderl","year":"2006","unstructured":"Faderl S, Verstovsek S, Cortes J, Ravandi F, Beran M, Garcia-Manero G, Ferrajoli A, Estrov Z, O\u2019Brien S, Koller C, Giles FJ, Wierda W, Kwari M, Kantarjian HM (2006) Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50\u00a0years of age or older. Blood 108(1):45\u201351. doi: 10.1182\/blood-2005-08-3294","journal-title":"Blood"},{"issue":"6","key":"1862_CR27","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1200\/JCO.2003.04.031","volume":"21","author":"HM Kantarjian","year":"2003","unstructured":"Kantarjian HM, Gandhi V, Kozuch P, Faderl S, Giles F, Cortes J, O\u2019Brien S, Ibrahim N, Khuri F, Du M, Rios MB, Jeha S, McLaughlin P, Plunkett W, Keating M (2003) Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers. J Clin Oncol 21(6):1167\u20131173","journal-title":"J Clin Oncol"},{"issue":"1","key":"1862_CR28","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/j.1600-0609.2011.01703.x","volume":"88","author":"S Buchholz","year":"2012","unstructured":"Buchholz S, Dammann E, Stadler M, Krauter J, Beutel G, Trummer A, Eder M, Ganser A (2012) Cytoreductive treatment with clofarabine\/ara-C combined with reduced-intensity conditioning and allogeneic stem cell transplantation in patients with high-risk, relapsed, or refractory acute myeloid leukemia and advanced myelodysplastic syndrome. Eur J Haematol 88(1):52\u201360. doi: 10.1111\/j.1600-0609.2011.01703.x","journal-title":"Eur J Haematol"},{"issue":"7","key":"1862_CR29","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.bbmt.2010.10.016","volume":"17","author":"S Srivastava","year":"2011","unstructured":"Srivastava S, Jones D, Wood LL, Schwartz JE, Nelson RP Jr, Abonour R, Secrest A, Cox E, Baute J, Sullivan C, Kane K, Robertson MJ, Farag SS (2011) A phase I trial of high-dose clofarabine, etoposide, and cyclophosphamide and autologous peripheral blood stem cell transplantation in patients with primary refractory and relapsed and refractory non-Hodgkin lymphoma. Biol Blood Marrow Transplant 17(7):987\u2013994. doi: 10.1016\/j.bbmt.2010.10.016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"1862_CR30","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/leu.2010.319","volume":"25","author":"SS Farag","year":"2011","unstructured":"Farag SS, Wood LL, Schwartz JE, Srivastava S, Nelson RP Jr, Robertson MJ, Abonour R, Secrest A, Cox E, Baute J, Sullivan C, Kane K, Jones DR (2011) Phase I trial and pharmacokinetic study of high-dose clofarabine and busulfan and allogeneic stem cell transplantation in adults with high-risk and refractory acute leukemia. Leukemia 25(4):599\u2013605. doi: 10.1038\/leu.2010.319","journal-title":"Leukemia"},{"issue":"15","key":"1862_CR31","doi-asserted-by":"crossref","first-page":"4258","DOI":"10.1182\/blood-2011-06-358010","volume":"118","author":"J Magenau","year":"2011","unstructured":"Magenau J, Tobai H, Pawarode A, Braun T, Peres E, Reddy P, Kitko C, Choi S, Yanik G, Frame D, Harris A, Erba H, Kujawski L, Elenitoba-Johnson K, Sanks J, Jones D, Paczesny S, Ferrara J, Levine J, Mineishi S (2011) Clofarabine and busulfan conditioning facilitates engraftment and provides significant antitumor activity in nonremission hematologic malignancies. Blood 118(15):4258\u20134264. doi: 10.1182\/blood-2011-06-358010","journal-title":"Blood"},{"issue":"6","key":"1862_CR32","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.bbmt.2010.09.022","volume":"17","author":"BS Andersson","year":"2011","unstructured":"Andersson BS, Valdez BC, de Lima M, Wang X, Thall PF, Worth LL, Popat U, Madden T, Hosing C, Alousi A, Rondon G, Kebriaei P, Shpall EJ, Jones RB, Champlin RE (2011) Clofarabine +\/\u2212 fludarabine with once daily i.v. busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDS. Biol Blood Marrow Transplant 17(6):893\u2013900. doi: 10.1016\/j.bbmt.2010.09.022","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"1862_CR33","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/j.bbmt.2012.06.010","volume":"18","author":"P Kebriaei","year":"2012","unstructured":"Kebriaei P, Basset R, Ledesma C, Ciurea S, Parmar S, Shpall EJ, Hosing C, Khouri I, Qazilbash M, Popat U, Alousi A, Nieto Y, Jones RB, de Lima M, Champlin RE, Andersson BS (2012) Clofarabine combined with busulfan provides excellent disease control in adult patients with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 18(12):1819\u20131826. doi: 10.1016\/j.bbmt.2012.06.010","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"1862_CR34","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/j.1600-0609.2012.01822.x","volume":"89","author":"P Chevallier","year":"2012","unstructured":"Chevallier P, Labopin M, Buchholz S, Ganser A, Ciceri F, Lioure B, Faul C, Guillerm G, Finke J, Huynh A, Schubert J, Kolb HJ, Polge E, Nagler A, Mohty M (2012) Clofarabine-containing conditioning regimen for allo-SCT in AML\/ALL patients: a survey from the Acute Leukemia Working Party of EBMT. Eur J Haematol 89(3):214\u2013219. doi: 10.1111\/j.1600-0609.2012.01822.x","journal-title":"Eur J Haematol"},{"issue":"12","key":"1862_CR35","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1038\/bmt.2010.32","volume":"45","author":"FL Locke","year":"2010","unstructured":"Locke FL, Artz A, Rich E, Zhang Y, van Besien K, Stock W (2010) Feasibility of clofarabine cytoreduction before allogeneic transplant conditioning for refractory AML. Bone Marrow Transplant 45(12):1692\u20131698. doi: 10.1038\/bmt.2010.32","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"1862_CR36","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1592\/phco.31.9.923","volume":"31","author":"PE Kintzel","year":"2011","unstructured":"Kintzel PE, Visser JA, Campbell AD (2011) Clofarabine-associated acute kidney injury and proteinuria. Pharmacotherapy 31(9):923. doi: 10.1592\/phco.31.9.923","journal-title":"Pharmacotherapy"},{"key":"1862_CR37","unstructured":"Mineishi S, Magenau J, Tobai H, Pwarode A, Peres EM, Reddy P, Kitko K, Choi S, Erba HP, Kujawski L, Yanik G, Ferrara J, Levine JE (2010) Allogeneic hematopoietic stem cell transplantation with clofarabine\/busulfan x 4 (CloBu 4) conditioning exhibits significant anti-tumor activity in non-remission hematologic malignancies, especially in AML. Blood (ASH Annual Meeting Abstracts), Nov 2010; 116: 35"},{"issue":"10","key":"1862_CR38","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1038\/bmt.2010.309","volume":"46","author":"N Atimere","year":"2011","unstructured":"Atimere N, Zriba S, Hicheri Y, Pautas C, Cordonnier C, Maury S (2011) Clofarabine as a potential stimulant of alloreactivity. Bone Marrow Transplant 46(10):1393\u20131394. doi: 10.1038\/bmt.2010.309","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"1862_CR39","doi-asserted-by":"crossref","first-page":"3156","DOI":"10.1182\/blood.V98.10.3156","volume":"98","author":"S Maury","year":"2001","unstructured":"Maury S, Salomon B, Klatzmann D, Cohen JL (2001) Division rate and phenotypic differences discriminate alloreactive and nonalloreactive T cells transferred in lethally irradiated mice. Blood 98(10):3156\u20133158","journal-title":"Blood"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-013-1862-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-013-1862-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-013-1862-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T16:43:14Z","timestamp":1596300194000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-013-1862-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8,9]]},"references-count":39,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["1862"],"URL":"https:\/\/doi.org\/10.1007\/s00277-013-1862-6","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,8,9]]}}}